DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
” - 1 Nelsan - 1 Pauline Maki - 1 David Curtis - 1 Kejal - 1 Kantarci - 1 Andrea Lenzi - 1 University of Rome La Sapienza - 1
Top related locs:
Danish Denmark Chicago neuroradiology Rochester , Minnesota Taiwan Melbourne Australia
Top related orgs:
CNN - 1 Danish Dementia Research - 1 Copenhagen University Hospital Rigshospitalet - 1 University of Illinois - 1 UCL Genetics Institute - 1 University College London - 1 Mayo Clinic - 1 University of Rome La - 1

Search resuls for: "Dementia Research"


4 mentions found


☆ HRT use by younger women linked to dementia, study says. Experts disagree
  + stars: | 2023-06-28 | by ( Sandee Lamotte | ) edition.cnn.com   time to read: +7 min
However, experts who treat and study menopause say the study is unable to draw a direct connection to later-life dementia and that the overall benefits of hormone replacement therapy, or HRT, far outweigh the risks for many patients. “One finding in the study was a link between dementia and the use of HRT for a very short time span, under a year. Researchers compared people with dementia who had used hormone therapy, even briefly, with those from the larger group who had not. The chance of being diagnosed with dementia went up with years spent on HRT, the study found. When women used 12 or more years of hormone therapy, the association with a diagnosis of dementia rose to 74%, Pourhadi said.
Persons: ”, Nelsan, Pauline Maki, David Curtis, Kejal, Kantarci, Andrea Lenzi, University of Rome La Sapienza, ” Pourhadi, Pourhadi, Maki, ” Maki, Susan Davis, Amanda Heslegrave, ” Heslegrave Organizations: CNN, Danish Dementia Research, Copenhagen University Hospital Rigshospitalet, University of Illinois, UCL Genetics Institute, University College London, Mayo Clinic, University of Rome La, University of Illinois’s Center for Research, Women’s, Monash University, Dementia Research Locations: Danish, Denmark, Chicago, neuroradiology, Rochester , Minnesota, Taiwan, Melbourne, Australia, London
☆ Study reveals how treating hearing loss could impact dementia risk
  + stars: | 2023-04-13 | by ( Madeline Holcombe | ) edition.cnn.com   time to read: +5 min
CNN —Treating hearing loss could mean reducing the risk for dementia, according to a new study. Hearing loss may increase the risk for dementia, but using hearing aids lowered the risk so it’s similar to those without hearing loss, according to the study published Thursday in The Lancet. A 2020 Lancet commission on dementia prevention, intervention and care suggested hearing loss may be associated with around 8% of dementia cases, but this study found that the use of hearing aids reduced the risk to levels similar to people without hearing loss, the study said. “A recent study showed that only 15% of US adults with hearing loss use hearing aids,” De Sousa said. The Hearing Loss Association of America still supports multiple avenues for addressing hearing loss, Hamlin said.
☆ Putin took cancer drugs that warped his decision-making on Ukraine, Danish intel says, reviving disputed theories about his health
  + stars: | 2022-12-30 | by ( Joshua Zitser | ) www.businessinsider.com   time to read: +4 min
A Danish intelligence official said Putin was taking thyroid-cancer drugs in February 2022. He told Danish media the drugs can cause "delusions of grandeur" and may have warped his thinking. The claim was reported by the Danish newspaper Berlingske based on an interview with the head of the Russia analysis team for its national defense intelligence agency, Forsvarets Efterretningstjeneste (FE). He told the newspaper that Putin was taking hormones to treat thyroid cancer in February 2022, and that it likely affected his mental capacity. The Danish official also spoke to Berlingske in guarded language, asserting that reports of Putin having had thyroid cancer were "definitely a good bet."
☆ Experimental drug appears to slow progression of Alzheimer’s disease in clinical trial but raises safety concerns
  + stars: | 2022-11-29 | by ( Jacqueline Howard | ) edition.cnn.com   time to read: +11 min
It involved 1,795 adults, ages 50 to 90, with mild cognitive impairment due to early Alzheimer’s disease or mild Alzheimer’s disease-related dementia. Such a score is consistent with early Alzheimer’s disease, with a higher number associated with more cognitive impairment. By 18 months, the CDR-SB score went up 1.21 points in the lecanemab group, compared with 1.66 in the placebo group. Overall, there were serious adverse events in 14% of the lecanemab group and 11.3% of the placebo group. The researchers also wrote that about 0.7% of participants in the lecanemab group and 0.8% of those in the placebo group died, corresponding to six deaths documented in the lecanemab group and seven in the placebo group.
0 next >>
Total: 4